---
title: "DAJIAWEIKANG: The share reduction plan of the concerted parties of the controlling shareholder expired without any shares being reduced"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289176124.md"
description: "DAJIAWEIKANG announced that its controlling shareholder and the concerted party of the actual controller, Tongjia Investment, originally planned to reduce its holdings by no more than 6.1621 million shares through centralized bidding or block trading from March 10 to June 9, 2026. As of June 9, the reduction plan expired, and Tongjia Investment did not reduce its holdings in the company, maintaining 9.8 million shares before and after the reduction, accounting for 4.77%. This reduction complies with regulations, does not violate the reduction plan and commitments, and will not affect the company's control, governance, and operations"
datetime: "2026-06-09T10:45:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289176124.md)
  - [en](https://longbridge.com/en/news/289176124.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289176124.md)
generator: "portal-rs"
---

# DAJIAWEIKANG: The share reduction plan of the concerted parties of the controlling shareholder expired without any shares being reduced

DAJIAWEIKANG announced that its controlling shareholder and the concerted party of the actual controller, Tongjia Investment, originally planned to reduce its holdings by no more than 6.1621 million shares through centralized bidding or block trading from March 10 to June 9, 2026. As of June 9, the reduction plan expired, and Tongjia Investment did not reduce its holdings in the company, maintaining 9.8 million shares, accounting for 4.77%. This reduction complies with regulations, does not violate the reduction plan and commitments, and will not affect the company's control, governance, or operations

### Related Stocks

- [301126.CN](https://longbridge.com/en/quote/301126.CN.md)

## Related News & Research

- [CSPC’s SYS6010 Wins Third Breakthrough Therapy Tag in High-Need Cancer Indications](https://longbridge.com/en/news/297638498.md)
- [H.U. Group unit Fujirebio wins Health Canada licenses for Lumipulse neurology blood tests](https://longbridge.com/en/news/297597814.md)
- [China Risun Group: Net profit jumped 376% on higher margins and new energy growth, with a major battery materials acquisition](https://longbridge.com/en/news/297330227.md)
- [BioVersys says FDA grants Fast Track designation for BV100 antibiotic candidate](https://longbridge.com/en/news/297733781.md)
- [Firehawk completes six-for-six Hydra-70 live-fire test, collects ballistic flight data](https://longbridge.com/en/news/297532316.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**